SLC1A5 and cancer: The in vivo efficacy of V-9302 suggests that it causes sufficient disruption to AA homeostasis, potentially in combination with other effects, to be a promising candidate for cancer therapy, but its actions cannot be explained by inhibition of ASCT2.